PDF(Pubmed)
Abstract：
UNASSIGNED: Stereotactic radiotherapy (SBRT) potentially has a role in the management of oligometastatic melanoma. However, literature with data specific to this management is very limited. The objectives of this study were to evaluate the time to local control (LC) of extra-cranial melanoma metastases after SBRT treatment and to help establish if SBRT is a useful therapy for oligometastatic melanoma.
UNASSIGNED: A retrospective study was conducted with data collected from two referral centers in France between 2007 and 2020. The oligometastatic status of patients was reported based on the latest recommendations with a maximum of three lesions prior to treatment.
UNASSIGNED: A total of 69 patients receiving SBRT for 88 oligometastatic melanoma metastases were included. The median follow-up time was 42.6 months. Most patients were treated for metachronous oligometastatic lesions. Occurrence of oligoprogression, oligorecurrence, and oligopersistence was reported in 42.0%, 39.1%, and 17.4% of cases, respectively. Treated lesions were mostly pulmonary (40.6%), followed by lymph node (34.8%) and hepatic sites (24.6%). Progression-free survival at 1, 2, and 3 years were 47.0% (35-59), 27.0% (16-39), and 25.0% (15.0-37.0), respectively. Time to LC rates at 1, 2, and 3 years were 94.2% (87.0-98.1), 90.3% (81.3-96.1), and 90.3% (81.3-96.1), respectively. Overall survival at 1, 2, and 3 years were 87% (76.0-93.0), 74.0% (76.0-93.0), and 61.0% (47.0-73.0), respectively. Only 17.4% of patients experienced acute, grade 1 or grade 2 toxicities with no reports of grade 3 or higher toxicities.
UNASSIGNED: SBRT demonstrated efficacy in managing melanoma patients with extracranial oligometastases and showed an overall low toxicity profile. Future randomized studies are needed to establish the role of SBRT in therapeutic approaches for patients with oligometastatic melanoma.
UNASSIGNED: A retrospective study was conducted with data collected from two referral centers in France between 2007 and 2020. The oligometastatic status of patients was reported based on the latest recommendations with a maximum of three lesions prior to treatment.
UNASSIGNED: A total of 69 patients receiving SBRT for 88 oligometastatic melanoma metastases were included. The median follow-up time was 42.6 months. Most patients were treated for metachronous oligometastatic lesions. Occurrence of oligoprogression, oligorecurrence, and oligopersistence was reported in 42.0%, 39.1%, and 17.4% of cases, respectively. Treated lesions were mostly pulmonary (40.6%), followed by lymph node (34.8%) and hepatic sites (24.6%). Progression-free survival at 1, 2, and 3 years were 47.0% (35-59), 27.0% (16-39), and 25.0% (15.0-37.0), respectively. Time to LC rates at 1, 2, and 3 years were 94.2% (87.0-98.1), 90.3% (81.3-96.1), and 90.3% (81.3-96.1), respectively. Overall survival at 1, 2, and 3 years were 87% (76.0-93.0), 74.0% (76.0-93.0), and 61.0% (47.0-73.0), respectively. Only 17.4% of patients experienced acute, grade 1 or grade 2 toxicities with no reports of grade 3 or higher toxicities.
UNASSIGNED: SBRT demonstrated efficacy in managing melanoma patients with extracranial oligometastases and showed an overall low toxicity profile. Future randomized studies are needed to establish the role of SBRT in therapeutic approaches for patients with oligometastatic melanoma.
摘要：
■立体定向放疗（SBRT）可能在寡转移型黑色素瘤的治疗中发挥作用。然而,具有特定于这种管理的数据的文献非常有限。这项研究的目的是评估SBRT治疗后颅外黑色素瘤转移的局部控制（LC）时间，并帮助确定SBRT是否是寡转移黑色素瘤的有用疗法。
■对2007年至2020年法国两个转诊中心收集的数据进行了回顾性研究。根据最新的建议报告患者的寡转移状态，治疗前最多三个病变。
■共包括69例接受SBRT治疗88例寡转移黑色素瘤的患者。中位随访时间为42.6个月。大多数患者接受了异时寡转移病变的治疗。寡头进展的发生，少复发，寡见性报告为42.0%，39.1%,和17.4%的病例，分别。经治疗的病灶主要为肺部（40.6%），其次是淋巴结（34.8％）和肝部位（24.6％）。1年、2年和3年的无进展生存率为47.0%（35-59），27.0%（16-39），和25.0%（15.0-37.0），分别。1年、2年和3年的LC发生率为94.2%(87.0-98.1)，90.3%（81.3-96.1），和90.3%（81.3-96.1），分别。1年，2年和3年的总生存率为87％（76.0-93.0），74.0%（76.0-93.0），和61.0%（47.0-73.0），分别。只有17.4%的患者经历急性，1级或2级毒性，没有3级或更高毒性的报告。
■SBRT证明了治疗黑色素瘤患者颅外寡转移的有效性，并显示出总体低毒性。未来的随机研究需要确定SBRT在寡转移型黑色素瘤患者治疗方法中的作用。
■对2007年至2020年法国两个转诊中心收集的数据进行了回顾性研究。根据最新的建议报告患者的寡转移状态，治疗前最多三个病变。
■共包括69例接受SBRT治疗88例寡转移黑色素瘤的患者。中位随访时间为42.6个月。大多数患者接受了异时寡转移病变的治疗。寡头进展的发生，少复发，寡见性报告为42.0%，39.1%,和17.4%的病例，分别。经治疗的病灶主要为肺部（40.6%），其次是淋巴结（34.8％）和肝部位（24.6％）。1年、2年和3年的无进展生存率为47.0%（35-59），27.0%（16-39），和25.0%（15.0-37.0），分别。1年、2年和3年的LC发生率为94.2%(87.0-98.1)，90.3%（81.3-96.1），和90.3%（81.3-96.1），分别。1年，2年和3年的总生存率为87％（76.0-93.0），74.0%（76.0-93.0），和61.0%（47.0-73.0），分别。只有17.4%的患者经历急性，1级或2级毒性，没有3级或更高毒性的报告。
■SBRT证明了治疗黑色素瘤患者颅外寡转移的有效性，并显示出总体低毒性。未来的随机研究需要确定SBRT在寡转移型黑色素瘤患者治疗方法中的作用。
